The US Medicare Payment Advisory Commission is finally able to analyze the impact of rebates on drug pricing in the Part D pharmacy benefit program – but will have to adopt a wait-and-see approach to recommending new policies given the expected impact of the Inflation Reduction Act.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?